Biopharamaceutical companies Oncothyreon Inc. (ONTY) and Array BioPharma Inc. (ARRY), Thursday said it joined hands to develop and commercialize ARRY-380, a selective small-molecule that have the potential to inhibit HER2 in metastatic breast cancer patients. ARRY-380 is an orally active and reversible compound. In studies, it has demonstrated additive tumor growth inhibition in combination with the standard-of-care therapeutics Herceptin or Taxotere.
HER2, also known as ErbB2, is a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers such as gastric and ovarian cancer.
As per the agreement, Oncothyreon will pay Array a fee of $10 million upon initiation of the collaboration, will fund and conduct the clinical development of ARRY-380 through a defined set of combination proof-of-concept trials. The trials will include patients with brain metastases.
Oncothyreon and Array intend to jointly conduct Phase 3 development supported by the proof-of-concept studies, with each party retaining the right to opt out of further development and commercialization in exchange for a significant royalty. Outside the U.S., Oncothyreon will receive a double-digit royalty on net sales intended to approximate a fifty percent profit share, and the two companies will share equally the proceeds from any sublicense of marketing rights.
Further, in a separate statement the company said that it has agreed to sell 5 million shares of its common stock and warrants to purchase 5 million shares of common stock for gross proceeds of approximately $10 million. The common stock and warrants will be sold in units at an exercise price of $5 per share, and each unit at a price of $2. The net proceeds will be used to fund $10 million upfront fee payable to Array BioPharma Inc.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.